Growing interest in PSMA imaging using [⁶⁸Ga]- or [¹⁸F]-labeled ligands and PSMA-based radioligand therapy (RLT) of prostate cancer (PCa) prompted us to survey the global community on their experiences and expectations. Methods: A web-based survey was composed to interrogate areas specific to PET imaging, the clinical value chain, and RLT applications. International responses were collected in early 2022. In total, over 300 valid responses were received and evaluated. Results: Most responses (83%) were given by nuclear medicine specialists with extensive experience in PET. At 22% of sites, PCa ranked “top” in cancer-type–specific PET indications, with an average and median of 15% and 10% of all cases, respectively. The most frequently used PSMA PET tracers were [⁶⁸Ga]PSMA (32%) and [¹⁸F]PSMA-1007 (31%). Users reported a steady growth in PSMA PET and RLT over the past 5 y, averaging 50% and 82%, respectively, with a further 100% median growth projected over the next 5 y. Of note, more respondents indicated cognizance of personalized dosimetry than actually used it routinely. The most commonly identified barriers to future growth in PCa theranostics were radiopharmaceutical supply, reimbursement, staff availability, and buy-in of medical oncologists. Conclusion: Despite enthusiasm, this survey indicates variable adoption of PSMA imaging and RLT globally. Several challenges need to be addressed by the medical community, authorities, and patient advocacy groups in integrating PSMA-targeted theranostics into personalized medicine.

对使用 [ ⁶⁸ Ga] 或 [ ¹⁸ F] 标记的配体的 PSMA 成像和基于 PSMA 的前列腺癌 (PCa) 放射配体治疗 (RLT) 的兴趣日益浓厚，这促使我们调查全​​球社区的经验和期望。方法：进行了一项基于网络的调查，以询问 PET 成像、临床价值链和 RLT 应用的特定领域。2022 年初收集了国际回复。总共收到并评估了 300 多份有效回复。结果：大多数答复 (83%) 是由具有丰富 PET 经验的核医学专家提供的。在 22% 的站点中，PCa 在癌症类型特异性 PET 适应症中排名“最高”，平均和中位数分别为所有病例的 15% 和 10%。最常用的 PSMA PET 示踪剂是 [ ⁶⁸ Ga]PSMA (32%) 和 [ ¹⁸ F]PSMA-1007 (31%)。用户报告称，过去 5 年 PSMA PET 和 RLT 稳步增长，平均分别增长 50% 和 82%，预计未来 5 年将进一步增长 100%。值得注意的是，更多的受访者表示了解个性化剂量测定而不是实际常规使用。PCa 治疗诊断学未来增长的最常见障碍是放射性药物供应、报销、人员可用性和内科肿瘤学家的支持。结论：尽管热情高涨，但这项调查表明全球对 PSMA 成像和 RLT 的采用各不相同。在将 PSMA 靶向治疗学整合到个性化医疗中时，医学界、当局和患者权益保护团体需要解决几个挑战。